MM3 Stock Chart & Stats
€59.50
€3.00(3.26%)
At close: 4:00 PM EST
€59.50
€3.00(3.26%)
Day’s Range― - ―
52-Week Range€50.50 - €81.00
Previous CloseN/A
Volume0.00
Average Volume (3M)20.00
Market Cap
€3.73B
Enterprise Value€4.22B
Total Cash (Recent Filing)€490.25M
Total Debt (Recent Filing)€821.56M
Price to Earnings (P/E)31.2
Beta0.35
Next Earnings
Jul 30, 2026EPS Estimate
0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.35
Shares Outstanding59,654,854
10 Day Avg. Volume0
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio8.41
Price to Book (P/B)3.29
Price to Sales (P/S)3.44
P/FCF Ratio24.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€76.44Price Target Upside28.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)3.56
Revenue Forecast (FY)€1.42B
Bulls Say, Bears Say
Bulls Say
Cash GenerationMerit’s cash conversion is a durable strength: operating cash flow (~$297M TTM) and free cash flow (~$274M TTM) run ahead of reported earnings (operating cash/NI ≈1.37x). Strong FCF supports capex, organic investment, bolt-on M&A and liquidity needs without immediate reliance on external funding.
Improving Profitability & MarginsMerit has materially improved gross and net margins over multi-year periods, with gross margin near 49% and net margin roughly doubling since 2021. Sustained margin expansion increases cashflow resilience against pricing or volume headwinds and provides capacity to reinvest in higher-growth therapeutic lines.
Recurring Consumables & Therapy ExpansionMerit’s core business of single‑use, procedure-driven consumables yields recurring revenue tied to procedure volumes. The firm is strategically shifting mix toward faster-growing therapeutic products (notably oncology) and adding assets (Viewpoint, BioLife, C2) that expand higher-growth, higher-margin clinical use cases.
Bears Say
Elevated Debt StockAlthough leverage indicators have improved (debt/equity ~0.52 TTM), absolute debt (~$846M) is meaningfully higher than earlier years. That elevated debt level can constrain financial flexibility if margins or organic growth slip, limiting capacity for large M&A, aggressive buybacks, or cyclical downside absorption.
Decelerating Organic GrowthRecent organic growth has slowed vs prior multi-year trends, with Q1 organic cc at 2.7% and guidance only mid-single digits. Persistent deceleration reduces operating leverage, increases reliance on acquisitions to hit targets, and makes margin and cashflow improvements harder to sustain absent secular procedure-volume recovery.
Tariff & Regional/ OEM HeadwindsMaterial and uncertain tariff costs (~$15M annualized in 2026) create structural gross‑margin pressure and cash unpredictability until resolution. Coupled with OEM revenue declines and APAC softness, these factors can weigh on sustained margin expansion and complicate pricing, sourcing and contract negotiations over coming quarters.
MM3 FAQ
What was Merit Medical’s price range in the past 12 months?
Merit Medical lowest stock price was €50.50 and its highest was €81.00 in the past 12 months.
What is Merit Medical’s market cap?
Merit Medical’s market cap is €3.73B.
When is Merit Medical’s upcoming earnings report date?
Merit Medical’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Merit Medical’s earnings last quarter?
Merit Medical released its earnings results on Apr 30, 2026. The company reported €0.823 earnings per share for the quarter, beating the consensus estimate of €0.73 by €0.094.
Is Merit Medical overvalued?
According to Wall Street analysts Merit Medical’s price is currently Undervalued.
Does Merit Medical pay dividends?
Merit Medical does not currently pay dividends.
What is Merit Medical’s EPS estimate?
Merit Medical’s EPS estimate is 0.84.
How many shares outstanding does Merit Medical have?
Merit Medical has 59,654,854 shares outstanding.
What happened to Merit Medical’s price movement after its last earnings report?
Merit Medical reported an EPS of €0.823 in its last earnings report, beating expectations of €0.73. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Merit Medical?
Currently, no hedge funds are holding shares in DE:MM3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merit Medical Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€76.44 (28.46% Upside)
€76.44 (28.46% Upside)
Blogger Sentiment
Bullish
DE:MM3 Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth €21.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.57%
12-Months-Change
Fundamentals
Return on Equity
8.95%
Trailing 12-Months
Asset Growth
10.18%
Trailing 12-Months
Company Description
Merit Medical
Merit Medical Systems, Inc. (MMSI) is engaged in the design, development, manufacturing, and worldwide commercialization of disposable medical products. These devices are crucial for a broad spectrum of diagnostic, therapeutic, and interventional procedures, primarily within the fields of cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two main divisions: Cardiovascular and Endoscopy. Its extensive product portfolio includes advanced solutions for diagnosing and treating conditions in peripheral vessels and organs, as well as a comprehensive suite of cardiac intervention products. The latter encompasses tools for vascular access, angiography, electrophysiology, cardiac rhythm management, fluid and hemodynamic monitoring, hemostasis, and various interventional therapies for heart-related ailments. Additionally, MMSI provides customized procedural solutions, offering critical care items, disinfection protection systems, specialized syringes, manifold kits, and tailored trays and packs. Their offerings further extend to coated tubes and wires, alongside sophisticated sensor components for microelectromechanical systems (MEMS). The company also features pulmonary products, such as laser-cut tracheobronchial stents with their accompanying over-the-wire and direct visualization delivery systems, and dilation balloons used for endoscopic stricture dilation. Gastroenterology products, as well as essential kits and accessories for endoscopy and bronchoscopy procedures, complete their diverse catalog. Merit Medical Systems sells its products to a wide client base, including hospitals and healthcare professionals (physicians, technicians, and nurses) working in alternative care settings. Distribution channels include a direct sales force, authorized distributors, original equipment manufacturer (OEM) partnerships, and custom procedure tray manufacturers, reaching customers throughout the United States and internationally. Founded in 1987, Merit Medical Systems, Inc. has its corporate headquarters situated in South Jordan, Utah.
MM3 Company Deck
MM3 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was largely positive: Merit beat revenue and earnings expectations in Q1, delivered the highest first-quarter operating margin in company history, generated stronger free cash flow, and closed strategic acquisitions (Viewpoint, BioLife, C2) that expand high-growth therapeutic markets. Near-term headwinds include a steep OEM decline in the quarter, tariff impacts and uncertainty, divestiture-related revenue drag, a recent Class I recall (managed as immaterial), and Q2 guidance reflecting some margin and EPS pressure. Management reiterated solid full-year guidance and confidence in organic and inorganic growth and emphasized disciplined cost/control efforts and platform alignment.View all DE:MM3 earnings summariesMM3 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€76.44
▲(28.46% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
ICU Medical
―
Lemaitre Vascular
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Options Prices
Currently, No data available
---








